期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.789941
关键词
choroidal metastasis; non-small cell lung carcinoma; EML4-ALK translocation; surgery; oligometastases; crizotinib
类别
资金
- Research Program of Chengdu University of Chinese Traditional Medicine [YYZX2020014]
Choroidal metastasis as an initial presenting feature of lung cancer with EML4-ALK translocation is rare and lacks effective treatment. This case study presents a 57-year-old woman with choroidal metastases secondary to lung cancer and EML4-ALK translocation, who achieved a rapid and complete response to oral administration of crizotinib without local treatment or systemic chemotherapy.
Choroidal metastasis as an initial presenting feature of lung cancer with EML4-ALK translocation is exceedingly rare and greatly impacts patient quality of life (QOL). There are no recommended treatments for such patients, and palliative care remains limited. It is unclear whether surgical resection of primary pulmonary lesions, systemic antitumor therapy, targeted therapy, or localized ocular therapy are effective in treating choroidal metastases in EML4-ALK rearranged oligometastatic non-small cell lung cancer (NSCLC). Here, we present the case of choroidal metastases secondary to lung cancer and EML4-ALK translocation in a 57-year-old woman who firstly underwent resection of lung lesions followed by oral administration of crizotinib without local treatment or systemic chemotherapy. Since then she had a rapid and complete response to crizotinib with 27 months of progression-free survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据